Physician profile
Mark A Glassner
NPI 1396746293
$1,163.32
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $170 · 2021: $104 · 2022: $157 · 2023: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $373.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $433.15 | 2019-2023 | |
| Astellas Pharma US INC | $72.65 | 2020-2023 | Veozah |
| Allergan, INC. | $72.23 | 2020 | |
| Idorsia Pharmaceuticals US INC | $67.20 | 2022-2023 | Quviviq |
| Novo Nordisk INC | $65.59 | 2020-2023 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $61.62 | 2022-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $53.23 | 2019-2021 | |
| Exact Sciences Corporation | $48.04 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $37.33 | 2019-2022 | |
| Lilly USA, LLC | $34.80 | 2019-2023 | Mounjaro |
| Amarin Pharma, INC. | $28.50 | 2019 | |
| Genentech USA, INC. | $27.79 | 2020 | |
| Seqirus USA INC | $25.61 | 2019-2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Teva Pharmaceuticals USA, INC. | $22.61 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.16 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $18.12 | 2022 | |
| Sanofi Pasteur INC. | $16.30 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.15 | 2019 | |
| Bausch Health US, LLC | $15.76 | 2021 | |
| Xeris Pharmaceuticals, INC. | $15.62 | 2023 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $12.86 | 2023 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Glassner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.